Showing results (161-170 of 216) with videos related to

Sort By:
Pageof 22
Frontiers in Medicine|June 18, 2026
Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EUCharlotte Van Isterdael, Edurne Mugarza, Piret Fischer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 8, 2020
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING studyEline van Overbeeke, Sissel Michelsen, Brett Hauber, et al.
The Biochemical Journal|November 6, 2003
BmTx3, a scorpion toxin with two putative functional faces separately active on A-type K+ and HERG currentsIsabelle Huys, Chen-Qi Xu, Cheng-Zhong Wang, et al.
Pharmaceuticals (Basel, Switzerland)|October 24, 2020
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in GermanyEvelien Moorkens, Teresa Barcina Lacosta, Arnold G Vulto, et al.
ESC Heart Failure|June 10, 2024
Heart failure patients' perspectives on treatment outcomes and unmet medical needs: A qualitative preference studyAlice Vanneste, Liese Barbier, Ramses Missotten, et al.
Frontiers in Pharmacology|May 7, 2026
International practices, barriers, and enablers for patient and public involvement in pricing and reimbursement decision-making: a mixed-methods studyAlice Vanneste, Morgane Deknudt, Elise Schoefs, et al.
Biomed Research International|May 29, 2014
Taking bacteriophage therapy seriously: a moral argumentGilbert Verbeken, Isabelle Huys, Jean-Paul Pirnay, et al.
Digital Health|July 5, 2022
Co-creation with research participants to inform the design of electronic informed consentEvelien De Sutter, David Geerts, Pascal Borry, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 2, 2021
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique surveyEline van Overbeeke, Brett Hauber, Sissel Michelsen, et al.
Cell and Tissue Banking|September 21, 2013
Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systemsJean-Paul Pirnay, Alain Vanderkelen, Daniel De Vos, et al.
Pageof 22